Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors

References

• Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, Korean Breast Cancer Society. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 2010; 123(1):177-87; PMID:20574671; https://doi.org/10.1007/s10549-010-0998-5
   PubMed Web of Science ®Google Scholar
• Pogoda K, Niwinska A, Murawska M, Pienkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 2013; 30(1):388; PMID:23292831; https://doi.org/10.1007/s12032-012-0388-4
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1):4429-34; PMID:17671126; https://doi.org/10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer 2012; 118(22):5463-72; PMID:22544643; https://doi.org/10.1002/cncr.27581
   PubMed Web of Science ®Google Scholar
• Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011; 117(8):1602-11; PMID:21472708; https://doi.org/10.1002/cncr.25746
   PubMed Web of Science ®Google Scholar
• Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst 2014; 106(2):djt376; PMID:24399849; https://doi.org/10.1093/jnci/djt376
   PubMedGoogle Scholar
• Irwin WJ, Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008; 44(18):2799-805; PMID:19008097; https://doi.org/10.1016/j.ejca.2008.09.034
   PubMed Web of Science ®Google Scholar
• Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9:R65; PMID:17910759; https://doi.org/10.1186/bcr1771
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. How basal are triple-negative breast cancers? Int J Cancer 2008; 123(1):236-40; PMID:18398844; https://doi.org/10.1002/ijc.23518
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98(19):10869-74; PMID:11553815; https://doi.org/10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16):5367-74; PMID:15328174; https://doi.org/10.1158/1078-0432.CCR-04-0220
   PubMed Web of Science ®Google Scholar
• Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19(2):264-71; PMID:16341146; https://doi.org/10.1038/modpathol.3800528
   PubMed Web of Science ®Google Scholar
• Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15(7):2302-10; PMID:19318481; https://doi.org/10.1158/1078-0432.CCR-08-2132
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ et al. Strategies for subtypes-dealing with diversity of breast cancer: Highlights of the St. Gallen internaional expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22(8):1736-47; PMID:21709140; https://doi.org/10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92(4):651-4; PMID:15700032; https://doi.org/10.1038/sj.bjc.6602419
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348(3):203-13; PMID:12529460; https://doi.org/10.1056/NEJMoa020177
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29(15):1949-55; PMID:21483002; https://doi.org/10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011; 58(7):1107-16; PMID:21707712; https://doi.org/10.1111/j.1365-2559.2011.03846.x
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14(2):R48; PMID:22420471; https://doi.org/10.1186/bcr3148
   PubMed Web of Science ®Google Scholar
• Tian T, Ruan M, Yang W, Shui R. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget 2016; 7(28):44395-405; PMID:27323808; https://doi.org/10.18632/oncotarget.10054
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, Tan PH, Iqbal J. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat 2016; 156(2):237-47; PMID:26960711; https://doi.org/10.1007/s10549-016-3743-x
   PubMed Web of Science ®Google Scholar
• Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat 2016; 158(2):323-31; PMID:27372069; https://doi.org/10.1007/s10549-016-3863-3
   PubMed Web of Science ®Google Scholar
• Yeat NC, Lin C, Sager M, Lin J. Cancer proteomics: Developments in technology, clinical use and commercialization. Expert Rev Proteomics 2015; 12(4):391-405; PMID:26145529; https://doi.org/10.1586/14789450.2015.1051969
   PubMed Web of Science ®Google Scholar
• Rogers S, Girolami M, Kolch W, Waters KM, Liu T, Thrall B, Wiley HS. Investigating the correspondance between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics 2008; 24(24):2894-900; PMID:18974169; https://doi.org/10.1093/bioinformatics/btn553
   PubMed Web of Science ®Google Scholar
• Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 2005; 4(11):1741-53; PMID:16091476; https://doi.org/10.1074/mcp.M500102-MCP200
   PubMed Web of Science ®Google Scholar
• Abramowitz M, Leyland-Jones B. A systems approach to clinical oncology: Focus on breast cancer. Proteome Sci 2006; 4(4):5; PMID:16595007; https://doi.org/10.1186/1477-5956-4-5
   PubMed Web of Science ®Google Scholar
• Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Abrogast S et al. Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteomics 2013; 12(9):2615-22; PMID:23653450; https://doi.org/10.1074/mcp.M112.023051
   PubMed Web of Science ®Google Scholar
• Berg D, Hipp S, Malinowsky K, Böllner C, Becker KF. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer 2010; 46(1):47-55; PMID:19914823; https://doi.org/10.1016/j.ejca.2009.10.016
   PubMed Web of Science ®Google Scholar
• Chung JY, Hewitt SM. A well-based reverse-phase protein array of formalin-fixed paraffin-embedded tissue. Methods Mol Biol 2015; 1312:129-39; PMID:26043998; https://doi.org/10.1007/978-1-4939-2694-7_17
   PubMedGoogle Scholar
• Bateman NW, Sun M, Bhargavva R, Hood BL, Darfler MM, Kovatich AJ, Hooke JA, Krizman DB, Conrads TP. Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. J Proteome Res 2011; 10(3):1323-32; PMID:21155598; https://doi.org/10.1021/pr101073s
   PubMed Web of Science ®Google Scholar
• Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M et al. Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications. Cancer Res 2015; 75(11):2243-53; PMID:25883093; https://doi.org/10.1158/0008-5472.CAN-14-1937
   PubMed Web of Science ®Google Scholar
• Kennedy JJ, Whiteaker JR, Schoenherr RM, Yan P, Allison K, Shipley M, Lerch M, Hoofnagle AN, Baird GS, Paulovich AG. Optimized protocol for quantitative multiple reaction monitoring-based proteomic analysis of formalin-fixed, paraffin-embedded tissues. J Proteome Res 2015; 15(8):2717-28; PMID:27462933; https://doi.org/10.1021/acs.jproteome.6b00245
   PubMed Web of Science ®Google Scholar
• Alkhas A, Hood BL, Oliver K, Teng PN, Oliver J, Mitchell D, Hamilton CA, Maxwell GL, Conrads TP. Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue. J Proteome Res 2010; 10(11):5264-71; PMID:21932769; https://doi.org/10.1021/pr2007736
   PubMed Web of Science ®Google Scholar
• Cheung W, Darfler MM, Alvarez H, Hood BL, Conrads TP, Habbe N, Krizman DB, Mollenhauer J, Feldmann G, Maitra A. Application of a global proteomic approach to archival precursor lesions: Deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregultated in pancreatic cancer precursors. Pancreatology 2008; 8(6):608-16; PMID:18849643; https://doi.org/10.1159/000161012
   PubMed Web of Science ®Google Scholar
• Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted JC, Krizman DB, Veenstra TD, Gutkind JS. Proteomics analysis of laser-captured paraffin-embedded tissues: A molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14(4):1002-14; PMID:18281532; https://doi.org/10.1158/1078-0432.CCR-07-1497
   PubMed Web of Science ®Google Scholar
• Sprung RW, Martinez MA, Carpenter KL, Ham AJ, Washington MK, Arteaga CL, Sanders ME, Liebler DC. Precision of multiple reaction monitoring mass-spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J Proteome Res 2012; 11(6):3498-505; PMID:22530795; https://doi.org/10.1021/pr300130t
   PubMed Web of Science ®Google Scholar
• Guzel C, Ursem NT, Dekker LJ, Derkx P, Joore J, van Dijk E, Ligtvoet G, Steegers EA, Luider TM. Multiple reaction monitoring assay for pre-eclampsia related calcyclin peptides in formalin fixed paraffin embedded placenta. J Proteome Res 2011; 10(7):3274-82; PMID:21329384; https://doi.org/10.1021/pr1010795
   PubMed Web of Science ®Google Scholar
• Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, Weil RJ, DeVoe DL, Lee CS, Balgley BM. Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem 2007; 55(7):763-72; PMID:17409379; https://doi.org/10.1369/jhc.7A7177.2007
   PubMed Web of Science ®Google Scholar
• Tanca A, Pagnozzi D, Burrai GP, Polinas M, Uzzau S, Antuofermo E, Addis MF. Comparability of differential proteomics data generated from paired archival fresh-frozen and formalin-fixed samples by GeLC-MS/MS and spectral counting. J Proteomics 2012; 77:561-76; PMID:23043969; https://doi.org/10.1016/j.jprot.2012.09.033
   PubMed Web of Science ®Google Scholar
• Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005; 7(3):R365-73; PMID:15987432; https://doi.org/10.1186/bcr1006
   PubMed Web of Science ®Google Scholar
• Ma L, Jiang T. Clinical implications of Ezrin and CD44 co-expression in breast cancer. Oncol Rep 2013; 30(4):1899-905; PMID:23900701; https://doi.org/10.3892/or.2013.2641
   PubMed Web of Science ®Google Scholar
• Saito S, Yamamoto H, Mukaisho K, Sato S, Higo T, Hattori T, Yamamoto G, Sugihara H. Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS One 2013; 8(1):e54881; PMID:23357878; https://doi.org/10.1371/journal.pone.0054881
   PubMed Web of Science ®Google Scholar
• Machowska M, Wachowicz K, Sopel M, Rzepecki R. Nuclear localization of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer 2014; 14:142; PMID:24581141; https://doi.org/10.1186/1471-2407-14-142
   PubMed Web of Science ®Google Scholar
• Charette SJ, Landry J. The interactions of HSP27 with Daxx identifies a potential regulatory role of HSP27 in fas-induced apoptosis. Ann N Y Acad Sci 2000; 926:126-31; PMID:11193028; https://doi.org/10.1111/j.1749-6632.2000.tb05606.x
   PubMed Web of Science ®Google Scholar
• Gimenez M, Marie SK, Oba-Shinjo S, Uno M, Izumi C, Oliveira JB, Rosa JC. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendrioglioma. BMC Cancer 2015; 15:481; PMID:26108672; https://doi.org/10.1186/s12885-015-1473-9
   PubMed Web of Science ®Google Scholar
• Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 2011; 60(4):525-35; PMID:21207025; https://doi.org/10.1007/s00262-010-0961-7
   PubMed Web of Science ®Google Scholar
• Schölz C, Tampé R. The intracellular antigen transporter machinery TAP in adaptive immunity and virus escape mechanisms. J Bioenerg Biomembr 2005; 37(6):509-15; PMID:16691491; https://doi.org/10.1007/s10863-005-9500-1
   PubMed Web of Science ®Google Scholar
• Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: Do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest 2006; 35(3-4):485-503; PMID:16916763; https://doi.org/10.1080/08820130600808246
   PubMed Web of Science ®Google Scholar
• Whitford P, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett 1992; 61(2):157-64; PMID:1730139; https://doi.org/10.1016/0304-3835(92)90174-T
   PubMed Web of Science ®Google Scholar
• van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008; 123(3):609-15; PMID:18498132; https://doi.org/10.1002/ijc.23543
   PubMed Web of Science ®Google Scholar
• Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother 2012; 61(6):789-801; PMID:22065046; https://doi.org/10.1007/s00262-011-1137-9
   PubMed Web of Science ®Google Scholar
• Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000 Sep; 21(9):455-64; PMID:10953098; https://doi.org/10.1016/S0167-5699(00)01692-3
   PubMedGoogle Scholar
• López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176(6):3402-9; PMID:16517708; https://doi.org/10.4049/jimmunol.176.6.3402
   PubMed Web of Science ®Google Scholar
• Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y et al. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat 2016; 158(1):1-9; PMID:27260189; https://doi.org/10.1007/s10549-016-3848-2
   PubMed Web of Science ®Google Scholar
• Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ et al. Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Cancer Immunol Res 2016; 4(5):390-9; PMID:26980599; https://doi.org/10.1158/2326-6066.CIR-15-0243
   PubMed Web of Science ®Google Scholar
• Brucet M, Marqués L, Sebastián C, Lloberas J, Celada A. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. Genes Immun 2004; 5(1):26-35; PMID:14735146; https://doi.org/10.1038/sj.gene.6364035
   PubMed Web of Science ®Google Scholar
• Battle TE, Lynch RA, Frank DA. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 2006; 66(7):3649-57; PMID:16585190; https://doi.org/10.1158/0008-5472.CAN-05-3612
   PubMed Web of Science ®Google Scholar
• Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint\sVictor C, Cucolo L, Lee DS, Pauken KE, Huang AC et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 2016; 167(6):1540-54; PMID:27912061; https://doi.org/10.1016/j.cell.2016.11.022
   PubMed Web of Science ®Google Scholar
• Reading JL, Quezada SA. Too much of a good thing? Chronic IFN fuels resistance to cancer immunotherapy. Immunity 2016; 45(6):1181-3; PMID:28002724; https://doi.org/10.1016/j.immuni.2016.12.004
   PubMed Web of Science ®Google Scholar
• Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, Vieth M, Waldner M, Steinberg P, Hohenadl C et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis 2013; 34(1):153-62; PMID:23042300; https://doi.org/10.1093/carcin/bgs310
   PubMed Web of Science ®Google Scholar
• Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71(14):4809-20; PMID:21646474; https://doi.org/10.1158/0008-5472.CAN-11-0753
   PubMed Web of Science ®Google Scholar
• Campone M, Valo I, Jézéquel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, Guette C. Prediction of recurrence and survival for triple-negative breast cancer (TNBC) by a protein signature in tissue samples. Mol Cell Proteomics 2015; 14(11):2936-46; PMID:26209610; https://doi.org/10.1074/mcp.M115.048967
   PubMed Web of Science ®Google Scholar
• Tolstrup AB, Bejder A, Fleckner J, Justesen J. Transcriptional regulation of the interferon-gamma-inducible tryptophanyl-tRNA synthase includes alternative splicing. J Biol Chem 1995; 270(1):397-403; PMID:7814400; https://doi.org/10.1074/jbc.270.1.397
   PubMed Web of Science ®Google Scholar
• Otani A, Slike BM, Dorrell MI, Hood J, Kinder K, Ewalt KL, Cheresh D, Schimmel P, Friedlander M. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci U S A 2002; 99(1):178-83; PMID:11773625; https://doi.org/10.1073/pnas.012601899
   PubMed Web of Science ®Google Scholar
• Nakatani S, Wei M, Ishimura E, Kakehashi A, Mori K, Nishizawa Y, Inaba M, Wanibuchi H. Proteome analysis of laser capture microdissected glomeruli from formalin-fixed paraffin-embedded kidneys of autopsies of diabetic patients: Nephronectin is associated with the development of diabetic glomerulosclerosis. Nephrol Dial Transplant 2012; 27(5):1889-97; PMID:22172726; https://doi.org/10.1093/ndt/gfr682
   PubMed Web of Science ®Google Scholar
• Maes E, Valkenborg D, Mertens I, Broeckx V, Baggerman G, Sagaert X, Landuyt B, Prenen H, Schoofs L. Proteomic analysis of formalin-fixed paraffin-embedded colorectal cancer tissue using tandem mass tag protein labeling. Mol Biosyst 2013; 9(11):2686-95; PMID:23986405; https://doi.org/10.1039/c3mb70177h
   PubMed Web of Science ®Google Scholar
• Xiao Z, Li G, Chen Y, Li M, Peng F, Li C, Li F, Yu Y, Ouyang Y, Xiao Z et al. Quantitative proteomic analysis of formalin-fixed paraffin-embedded nasopharyngal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem 2010; 58(6):517-27; PMID:20124091; https://doi.org/10.1369/jhc.2010.955526
   PubMed Web of Science ®Google Scholar
• Jain MR, Li Q, Liu T, Rinaggio J, Ketkar A, Tournier V, Madura K, Elkabes S, Li H. Proteomic identification of immunoproteasome accumulation in formalin-fixed rodent spinal cords with experimental autoimmune encephalomyelitis. J Proteome Res 2012; 11(3):1791-803; PMID:22188123; https://doi.org/10.1021/pr201043u
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang Y, Guo S, Jin H, Wang W, Yang P. Large scale systematic proteomic quantification from non-metastatic to metastatic colorectal cancer. Sci Rep 2015; 15(5):12120; PMID:26175278; https://doi.org/10.1038/srep12120
   PubMed Web of Science ®Google Scholar
• Tanca A, Abbondio M, Pisanu S, Pagnozzi D, Uzzau S, Addis MF. Critical comparison of sample preparation strategies for shotgun proteomic analysis of formalin-fixed, paraffin-embedded samples: Insights from liver tissue. Clin Proteomics 2014; 11(1):28; PMID:25097466; https://doi.org/10.1186/1559-0275-11-28
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123(3):725-31; PMID:20020197; https://doi.org/10.1007/s10549-009-0674-9
   PubMed Web of Science ®Google Scholar
• Mihály Z, Kormos M, Lánczky A, Dank M, Budczies J, Szász MA, Győrffy B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat 2013; 140(2):219-32; PMID:23836010; https://doi.org/10.1007/s10549-013-2622-y
   PubMed Web of Science ®Google Scholar